News Breaks |
|
|
| December 12, 2012 |
| 06:56 EDT |  | LLY | Eli Lilly provides update on next steps for Solanezumab
Eli Lilly provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease. Following discussions with regulators in the U.S., Europe and Canada, Lilly plans to conduct an additional Phase 3 study of solanezumab in patients with mild Alzheimer's disease. Additional details, including study design and length, are still being determined. Lilly expects to initiate this study no later than 3Q2013. Based on recent meetings with the FDA, Lilly does not intend to submit a Biologics License Application at this time in the U.S. based solely on the existing analyses of data from the Expedition studies. Lilly will continue to analyze and discuss the data from the two, Phase 3, double-blind, placebo-controlled solanezumab Expedition studies with regulators globally to determine the regulatory paths forward in different regions. It is possible that different courses of action could be taken in different jurisdictions. |
|
|
News For LLY From The Last 14 Days Check below for free stories on LLY the last two weeks. |
|
|
| May 16, 2013 |
| 08:55 EDT |  | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
 Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
| May 9, 2013 |
| 11:01 EDT | | LLY | Sears Holdings names Jeff Balagna Chief Information Officer
Subscribe for More Information |
|
| May 6, 2013 |
| 18:42 EDT | | LLY | Eli Lilly and Boehringer announce results from Phase 3 study of linagliptin
Subscribe for More Information |
|
| 16:40 EDT | | LLY | Eli Lilly announces CEO Dr. John Lechleiter to undergo surgery
Subscribe for More Information |
|
|
|
|
|
